Haleon plc: Appointment of
Dawn Allen as Chief Financial Officer
24
April 2024: Haleon plc (the
"Company" or "Haleon") (LSE/NYSE:
HLN) today announces the appointment of
Dawn Allen as Chief Financial Officer ("CFO"). Dawn will join
Haleon on 28 October 2024 and will assume the role of CFO and join
the Board from 1 November 2024.
This appointment follows Tobias
Hestler informing the Board of his decision to step down from his
position as CFO to better balance work demands with the management
of a long-term health condition. Tobias will step down from the
Board on 1 November 2024 and will remain within the business until
the end of the year in order to ensure an orderly
transition.
Dawn is currently the CFO at Tate
& Lyle plc. Prior to joining Tate & Lyle, Dawn had a
25-year career at Mars Inc., where she was most recently Global CFO
and VP Global Transformation. Before that, she held a number of
senior financial roles in Europe and the US. Dawn also currently
serves as a Non-Executive Director and member of the Audit and Risk
Committee of ITV plc.
Brian McNamara, Haleon's Chief Executive Officer
commented: "We are delighted to have
appointed Dawn as our next CFO. She has a proven track record as a
CFO with extensive consumer and international experience and will
be a great addition to our executive team. I want to take this
opportunity to thank Tobias for his significant contribution in
creating Haleon as a standalone business and for the close
partnership over the last few years. He has played a critical role
in shaping and building Haleon's foundations and putting us on a
path for long-term success."
Sir
Dave Lewis, Haleon's Chair commented: "On behalf of the Board, I would like to thank Tobias for his
significant input to the Board and his strong support to Brian and
the management team and wish him all the very best for the future.
We are very pleased to appoint Dawn as Haleon's CFO. Dawn has deep
consumer and financial experience and will be a very welcome
addition to the Board."
Dawn Allen commented: "I am
very excited to join the team at Haleon. Its clear purpose and
fascinating journey through separation and beyond sets a strong
foundation for the future. I am looking forward to help shape the
next phase of the journey."
Tobias Hestler commented: "I
have been a Type 1 diabetic all my life and it's a condition that
has always needed careful management. That becomes even more
important as you get older and I've therefore concluded that after
30 years, now is the right time to step down and take my experience
into non-executive and advisory roles. I've had 15 fantastic years
helping bring together the businesses that Haleon has become and
listing the company. I'm very proud of the business we have built
and the potential that it has. I will continue at Haleon until the
end of this year and look forward to helping ensure an orderly
transition to Dawn as she takes on the role."
Haleon also separately announces
today the appointment of Line De Decker as Chief Human Resources
Officer. With over 27 years' experience, Line is currently Chief
People & Sustainability Officer at Aliaxis. Prior to that, she
held roles at GSK and DuPont, having started her career at PWC.
Line will join Haleon on 1 August 2024.
Notes to Editors
Biography
Dawn Allen
Dawn Allen
started her career in 1991 working for the auditing firm EY based
in the UK. In 1995, she joined Courtaulds plc in their
Corporate Finance department before moving to Mars Inc., in 1997
initially to work as Europe Confectionary Finance Manager spending
some time based in the Netherlands. She returned to
the UK in 2000 taking on Sales Finance and Financial
Controller roles before being appointed as Country CFO Mars
Chocolate UK in 2007.
In 2013 she moved to the
USA to act as Regional CFO Wrigley Americas before moving back
to London in 2016 to take on the role of Global
Divisional CFO, Food, Drinks and Multisales. Then, in 2020, she was
appointed as Global CFO & VP, Global Transformation at
Mars. In May 2022, Dawn was appointed CFO of Tate & Lyle
plc.
Dawn was appointed as a
Non-Executive Director and member of the Audit & Risk Committee
of ITV plc in October 2023. Dawn was
previously a Non-Executive Director of Tasty Bite Eatables Ltd, a
public company based in India. She holds a Bachelor of
Science in Chemistry at Bath University, UK, and is a member
of the Institute of Chartered Accountants
of England and Wales.
There is no further information to
be disclosed in respect of paragraph 9.6.13R of the UK Listing
Rules.
Remuneration Statement
Dawn Allen
Dawn's remuneration
arrangements on appointment have been set in
accordance with the Haleon Directors' Remuneration Policy approved
by shareholders at the 2023 AGM on 20 April 2023 and will
include:
|
●
|
Annual salary of
£730,000;
|
|
●
|
Benefits and pension contributions
in line with the Directors' Remuneration Policy (and aligned with
the majority of the wider UK workforce);
|
|
●
|
Provisions relating to annual bonus
and long-term incentive plans: a maximum AIP opportunity of 200% of
annual salary and a maximum PSP award of 350% of annual salary;
and
|
|
●
|
A pro-rated 2024 PSP award to
reflect her start date of 28 October 2024.
|
All incentive awards are subject to
malus and clawback provisions.
Dawn will receive replacement awards
to compensate the loss of incentive payments from her current
employment. These awards remain subject to performance conditions
where appropriate and will mirror, as closely as possible, the
value, terms and release timeline of the forfeited
awards.
Tobias Hestler
As required by section 430(2B) of the Companies Act 2006, details of
remuneration payments made or to be made to Tobias on stepping down
as a Director of the Company are detailed below.
Tobias's remuneration arrangements
in respect of his departure have been determined by the
Remuneration Committee in line with the Directors' Remuneration
Policy.
Tobias will continue to receive his
salary, pension and benefits until he leaves the business on 31
December 2024. Thereafter, he will be paid in lieu of notice for
the remainder of his 12-month notice period until 23 April 2025. A
capped contribution will be made to legal fees.
He will be considered an eligible
leaver and, in accordance with the Directors' Remuneration Policy,
will be eligible for a 2024 annual incentive award to be determined
by the Remuneration Committee in February 2025 and paid in March
2025, with 50% deferred for three years.
Outstanding deferred bonus awards
will be released on the original timetable, subject to malus and
clawback provisions.
Outstanding long-term incentive
awards will be pro-rated to the end of Tobias's employment and will
vest in line with the original vesting dates, subject to
satisfaction of the performance conditions.
All outstanding awards will remain
subject to malus and clawback provisions. His 2024 PSP award which
was granted in March 2024 will lapse.
Tobias's shareholding will be
subject to the share ownership guideline (350% of his current
salary or, if lower, his shareholding at the time of termination)
for a period of two years after the termination of his
employment.
Full remuneration arrangements for
the outgoing and the incoming CFO will be disclosed in the Annual
Report and Form-20F 2024 and subsequent years as
appropriate.
About Haleon
Haleon (LSE / NYSE: HLN) is a global
leader in consumer health, with a purpose to deliver better
everyday health with humanity. Haleon's product portfolio spans
five major categories - Oral Health, Pain Relief, Respiratory
Health, Digestive Health and Other, and Vitamins, Minerals and
Supplements (VMS). Its long-standing brands - such as Advil,
Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident,
parodontax and Centrum - are built on trusted science, innovation
and deep human understanding.
For more information, please
visit www.haleon.com.